Skip to content
Menu

Bio-Rad Laboratories, Inc. BIO

Full chart Compare
Set alert

Price alert · BIO

All alert types
358.90 USD -8.60 (-2.34%)

Regular-session close

358.90 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

353.31 Day range 369.44
236.73 52-week range 396.23
YTD
+18.45%
1 year
+18.21%

5D +1.40 (+0.39%)

360370380MonTueWedThuFri363.92
Market cap
9.65B
Revenue (ttm)
2.59B
Profit margin
39.45%
EPS (ttm)
37.64
Shares out
21.83M
P/E ratio
9.54
Forward P/E
36.19
YTD return
+18.45%
1-year return
+18.21%
50-day average
371.83
Volume
182.30K
Avg volume
260.18K
Open
364.34
Previous close
367.50
Day's range
353.31 – 369.44
52-week range
236.73 – 396.23
Beta
1.06
Analysts
Hold
Price target
356.67 (-0.6%)
Earnings date
Feb 11, 2027

Key statistics

200-day average
318.29
Enterprise value
9.58B
PEG ratio
4.01
Price / sales
3.72
Price / book
1.27
Revenue growth
0.50%
Free cash flow
271.65M
Total cash
1.66B
Total debt
1.36B
Return on equity
14.27%
Short % of float
7.21%

Fundamental scorecard

11 of 25 checks passed on BIO’s reported financials

ValueGrowthProfitabilityHealthDividend

11of 25 checks passed

  • Value 2 of 5
  • Growth 2 of 5
  • Profitability 2 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
BIO Revenue — quarterly 656.40M
BIO Net income — quarterly 458.60M
BIO EPS — quarterly 17.13

Earnings

BIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 20262.83———
Nov 4, 2026Sep 30, 20262.232.65+0.42+18.83%
Aug 4, 2026Jun 30, 20261.752.62+0.87+49.71%
Apr 30, 2026Mar 31, 20261.971.89-0.08-4.06%
Feb 12, 2026Dec 31, 20252.572.51-0.06-2.33%
Oct 29, 2025Sep 30, 20252.302.26-0.04-1.74%

Upgrades / downgrades

BIO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026RBC CapitalmainOutperformOutperform
Aug 7, 2026RBC CapitalmainOutperformOutperform
Aug 5, 2026CitigroupmainNeutralNeutral
Aug 5, 2026RBC CapitalmainOutperformOutperform
Aug 5, 2026Wells FargomainEqual-WeightEqual-Weight
May 1, 2026Wells FargomainEqual-WeightEqual-Weight

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
bio-rad.com

News

Your note

Sign in to keep a note on BIO — it syncs with the Stock Master app.

Insider holders

BIO insider holders
InsiderRelationLatest transactionDateShares held
ALLISON SCHWARTZDirectorConversion of Exercise of derivative securitySep 3, 20261,734
COREY COLLEENOfficerConversion of Exercise of derivative securitySep 4, 202519,550
CROWLEY MICHAEL WOfficerConversion of Exercise of derivative securityMar 13, 20258,171
DIVINCENZO JONATHAN PPresidentSaleNov 8, 20261,962
ENGELHARDT EVA ANETTEOfficerConversion of Exercise of derivative securitySep 3, 20261,828
EVRAN SEDATOfficerConversion of Exercise of derivative securityOct 19, 20264,160

Institution ownership

BIO institution ownership
Holder% heldSharesValueReported
First Eagle Investment Management, LLC11.25%2,455,580880.28MSep 29, 2026
Blackrock Inc.7.97%1,740,336623.88MSep 29, 2026
Dimensional Fund Advisors LP4.06%885,977317.61MSep 29, 2026
Vanguard Capital Management LLC3.79%827,202296.54MSep 29, 2026
Vanguard Portfolio Management LLC3.72%811,564290.93MSep 29, 2026
Ariel Investments, LLC3.62%789,341282.96MSep 29, 2026

Fund ownership

BIO fund ownership
Holder% heldSharesValueReported
First Eagle Funds-First Eagle Global Fund8.61%1,878,739673.49MJul 30, 2026
SmallCap World Fund Inc4.26%930,906333.71MSep 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF2.97%648,604232.51MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.68%584,782209.63MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.94%423,193151.71MJun 29, 2026
Ariel Investment Trust-Ariel Fund1.55%338,204121.24MSep 29, 2026